Logo Petros Pharmaceuticals, Inc. - PTPI 0.03 USD

EPS
-3.45
P/B
0.23
ROE
-92.93
Beta
2.03

0.032 USD

0.032 USD

Daily: -7.54%
Key Metrics

EPS: -3.45

Book Value: 0.31

Price to Book: 0.23

Debt/Equity: 235.49

% Insiders: 6.812%

Growth

Revenue Growth: -0.06%

Estimates

Forward P/E: -0.07

Forward EPS: -1.09

 Logo About Petros Pharmaceuticals, Inc. - (PTPI)

Country: United States

Sector: Health Care

Website: http://www.petrospharma.com

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Exchange Ticker
NCM (Australia) PTPI

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Dec. 1, 2022 0.10
Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion